Prescribing of smoking cessation medication in England since the introduction of varenicline.

AIMS To estimate the effect of the introduction of a new smoking cessation medication, varenicline, and the publication of guidance related to its use, on trends in prescribing of smoking cessation medications in England. DESIGN Interrupted time series analysis of primary care data on prescribing of smoking cessation medication using autoregressive integrated moving average (ARIMA) modelling. SETTING A total of 446 general practices included in The Health Improvement Network (THIN), a database of UK electronic primary care records. PARTICIPANTS All primary care patients registered with a THIN practice in England. MEASUREMENTS Monthly rates of prescribing of varenicline, nicotine replacement therapy (NRT) and bupropion per 100 000 patients registered with a THIN practice between June 2000 and June 2009. FINDINGS NRT was the most commonly prescribed stop smoking medication, and bupropion the least frequently prescribed. After its introduction in December 2006 varenicline rapidly became the second most commonly prescribed drug. There was no statistically significant change in overall prescribing for smoking cessation medications after its introduction (P = 0.760), or after the publication of the related guidance in July 2007 (P = 0.134). CONCLUSIONS Soon after being introduced in England, varenicline was widely prescribed; after nicotine replacement therapy it was the most commonly prescribed cessation medication. However, this does not appear to have increased overall rates of prescribing for smoking cessation medication.

[1]  Lisa Szatkowski,et al.  Validation of The Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications , 2010, Pharmacoepidemiology and drug safety.

[2]  J. Parton.  Smoking and Drinking , 1886, Hall's journal of health.

[3]  Helen Harris,et al.  Smoking and drinking among adults, 2009 , 2009 .

[4]  L. Stead,et al.  Nicotine receptor partial agonists for smoking cessation (Review) , 2007 .

[5]  J R Hughes,et al.  Antidepressants for smoking cessation. , 2014, The Cochrane database of systematic reviews.

[6]  Merete Osler,et al.  Effect of smoking reduction on lung cancer risk. , 2005, JAMA.

[7]  J. Gitchell,et al.  Impact of UK policy initiatives on use of medicines to aid smoking cessation , 2005, Tobacco Control.

[8]  Å. Westin,et al.  Effects of smoking cessation and reduction in asthmatics. , 2005, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[9]  R. West,et al.  GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales. , 2004, Addiction.

[10]  Josue P. Keely,et al.  Shape of the relapse curve and long-term abstinence among untreated smokers. , 2004, Addiction.

[11]  J. Vestbo,et al.  Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study , 2002, Thorax.

[12]  V. Hasselblad,et al.  Benefits of smoking cessation for longevity. , 2002, American journal of public health.

[13]  P M Barton,et al.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. , 2002, Health technology assessment.

[14]  D. Mant,et al.  Nicotine replacement therapy for smoking cessation. , 2004, The Cochrane database of systematic reviews.

[15]  R. Perera,et al.  Nicotine replacement therapy for smoking cessation. , 2012, The Cochrane database of systematic reviews.

[16]  S. Shapiro,et al.  Decline in the risk of myocardial infarction among women who stop smoking. , 1990, The New England journal of medicine.

[17]  S. Shapiro,et al.  The risk of myocardial infarction after quitting smoking in men under 55 years of age. , 1985, The New England journal of medicine.